AUPH - Aurinia Pharma EPS misses by $0.01 beats on revenue

Aurinia Pharma (NASDAQ:AUPH): Q2 GAAP EPS of -$0.37 misses by $0.01. Revenue of $6.62M (+21966.7% Y/Y) beats by $1.66M. Gross margin for the three and six months ended June 30, 2021 was ~95%. “As we continue to expand patient access to LUPKYNIS across the United States, we anticipate that annual net revenue for LUPKYNIS will be in the range of $40 to $50 million for 2021, setting Aurinia up for a very strong 2022 as we recognize the benefit of patients continuing on therapy and hopefully achieving reductions in their proteinuria,” said Peter Greenleaf, President and CEO. Shares +7.51%. Press Release

For further details see:

Aurinia Pharma EPS misses by $0.01, beats on revenue